Headlands Research Strengthens Its Position with New Acquisition
Headlands Research, a leading multinational organization specializing in clinical trials, has taken a significant step forward by acquiring Trial Management Associates (TMA). This acquisition not only expands its reach but also deepens its capability in conducting clinical research by leveraging TMA's rich network and expertise.
Expanded Clinical Network
TMA, a reputable multi-site clinical research entity, adds substantial value to Headlands Research's already robust network. With the acquisition, Headlands Research now boasts 21 sites across multiple regions, enhancing accessibility for sponsors seeking clinical trials. This strategic expansion nurtures diversity within the participant pools and enables broader geographic coverage, crucial for the successful conduct of clinical investigations.
Commitment to Strategic Growth
According to Kyle Burtnett, CEO of Headlands Research, "The acquisition of TMA illustrates our unyielding commitment to strategic growth in the realm of clinical trials." By employing TMA's established infrastructure and expertise, Headlands Research aims to provide sponsors with enhanced options in their clinical development journey, facilitating a seamless process that prioritizes patient welfare and research quality.
Unique Therapeutic Expertise
Located in Wilmington and Myrtle Beach, TMA brings with it significant expertise in various therapeutic areas, including vaccines and endocrinology. This wealth of experience will not only amplify Headlands Research's capabilities but also enrich its understanding of the therapeutic landscape. The collaboration aligns perfectly with Headlands Research's mission to advance innovative medical therapies aimed at improving patient outcomes.
Enhancing Patient Outcomes Together
President of TMA, Phil Dattilo, shared insights on the synergy between the two companies, stating that "the missions of TMA and Headlands Research are synchronous: to improve lives by advancing innovative medical therapies." This alignment indicates a strong collaboration moving forward, with shared best practices and pooled expertise designed to elevate the clinical trial experience and outcomes for participants.
About Headlands Research
Headlands Research is more than just a clinical trial site organization; it is a pioneering force in advancing healthcare improvements. With a mission centered around enhancing lives through medical innovation, they have successfully completed over 5,000 clinical trials. The organization's dedicated investigators are industry leaders with vast experience across an array of medical specialties, ensuring high-quality data and outcomes through expert recruitment and participation strategies.
Contact and Learn More
To get more information about Headlands Research and its impressive network of clinical trial sites, potential clients are encouraged to reach out directly. Headlands Research is dedicated to providing valuable insights into their operations and how they can assist in advancing medical research.
Frequently Asked Questions
What is the significance of Headlands Research acquiring TMA?
The acquisition allows Headlands Research to enhance its clinical trial capabilities, providing sponsors with more geographic options and diverse participant pools.
Who leads Trial Management Associates?
TMA is led by Phil Dattilo, who brings extensive experience in clinical research across various therapeutic areas.
How many sites does Headlands Research have after the acquisition?
Following the acquisition, Headlands Research operates a network of 21 clinical trial sites.
What areas of expertise does TMA provide?
TMA specializes in several areas, including vaccines and endocrinology, thereby enhancing Headlands Research's therapeutic capabilities.
How can someone learn more about Headlands Research?
Interested parties can visit the Headlands Research website for detailed information about their clinical trial services and research sites.
